Literature DB >> 25236315

Quality of life in patients with scalp psoriasis.

A Zampieron1, A Buja, M Fusco, D Linder, M Bortune, S Piaserico, V Baldo.   

Abstract

AIM: The aims of this study were to describe the quality of life (QoL) in patients suffering of scalp psoriasis and to assess the impact of the socio-demographic and clinical features of this condition on patients' health-related QoL, using general and specific QoL scales.
METHODS: This research is a cross-sectional study. The study involved 55 patients attending their first examination at the Dermatology Clinic of Padua University over the course of one year (April 2010-March 2011). The outcome was quality of life analyzed by means Scalpdex and SF-36 questionnaire.
RESULTS: The sample's mean Scalpdex score was 43.60±17.52, while the mean SF-36 score was 68.28±20.32. The SF-36 identified statistically significant differences between the psoriasis patients and the Italian general population in two domains, i.e. general health (P=0.0075) and emotional role (P=0.0048). The severity of patients' scalp lesions emerged as a factor associated with a reduced QoL in these patients, irrespective of the severity of their disease as a whole. Sex, age, schooling and other socio-demographic factors also characterized patients' perceived QoL.
CONCLUSION: Patients with scalp psoriasis suffered from a lower QoL relating to the highly visible site of their psoriatic lesions. Specific supportive measures should be dedicated to these patients by health care workers.

Entities:  

Mesh:

Year:  2014        PMID: 25236315

Source DB:  PubMed          Journal:  G Ital Dermatol Venereol        ISSN: 0392-0488            Impact factor:   2.011


  5 in total

1.  Clinical and trichoscopic aspects of scalp psoriasis: commentary to 'Clinical and trichoscopic features in various forms of scalp psoriasis' by F. Bruni et al.

Authors:  F Lacarrubba
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-09       Impact factor: 9.228

2.  Differences in Clinical Responses to Ustekinumab Treatment among Body Regions: Results from a Real-World Prospective, Observational, and Multi-Center Study in Korea.

Authors:  Sang Wook Son; Dae Young Yu; Youngdoe Kim; Hyo Hyun Ahn; Yong Hyun Jang; Joo Young Roh; Young Bok Lee; Ji Yeoun Lee; Myung Hwa Kim; YoungJa Lee; Gyeong-Hun Park; Hyun-Sun Yoon; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2022-01-27       Impact factor: 1.444

3.  Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.

Authors:  Leon Kircik; Joseph Fowler; Jonathan Weiss; Xiangyi Meng; Adriana Guana; Judit Nyirady
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-30

4.  Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis.

Authors:  Ulrich R Hengge; Kristina Röschmann; Henning Candler
Journal:  Psoriasis (Auckl)       Date:  2017-06-15

Review 5.  Psoriasis in children.

Authors:  Roxanne Pinson; Bahman Sotoodian; Loretta Fiorillo
Journal:  Psoriasis (Auckl)       Date:  2016-10-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.